Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2017-11-22 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
关于使用部分暂时闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Kunming Pharmaceutical Group Co., Ltd. regarding the use of temporarily idle raised funds for cash management. It references regulatory approvals, fundraising details, investment plans, and board and supervisory committee opinions. The document is relatively short (4121 characters) and primarily serves as a formal announcement of the company's plan to invest idle raised funds in low-risk financial products. It does not contain detailed financial statements or comprehensive financial performance data. It also includes opinions from independent directors, supervisory board, and the sponsoring institution, which is typical for announcements related to capital use. Therefore, this document is best classified as a Capital/Financing Update (CAP) rather than a full financial report or regulatory filing.
2017-11-22 Chinese
八届二十三次监事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed by the supervisory board (监事会) of Kunming Pharmaceutical Group Co., Ltd. It details voting results on proposals related to investment and cash management plans, and mentions that these proposals require further approval by a temporary shareholders' meeting. The document is short (607 characters) and serves as an official notice of board decisions rather than a full report or detailed financial disclosure. It does not contain financial statements, audit information, or detailed management discussion. It is not a report publication announcement since it contains substantive content about board resolutions and voting outcomes. The best fitting category is 'Board/Management Information' (MANG), as it announces decisions made by the company's supervisory board.
2017-11-22 Chinese
2017年第六次临时股东大会的法律意见
Regulatory Filings Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the procedures, attendance, and voting results of a specific shareholders' meeting (the 2017 sixth extraordinary general meeting) of Kunming Pharmaceutical Group Co., Ltd. It details the legality and validity of the meeting's convocation, attendance, and resolutions passed. It does not contain financial statements or detailed financial data, nor is it a report or announcement of financial results. It is not a proxy solicitation or voting results announcement per se, but a legal opinion on the meeting's compliance and validity. Given the nature of the document as a legal opinion on a shareholders' meeting, it best fits under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory or compliance documents that do not fit other specific categories.
2017-11-15 Chinese
2017年第六次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled as a resolution announcement for the 2017 sixth extraordinary general meeting of shareholders of Kunming Pharmaceutical Group Co., Ltd. It details the meeting date, attendance, voting results on a specific proposal, and legal verification by lawyers. The content focuses on the official announcement of voting results from a shareholder meeting, including vote counts and percentages, and legal compliance statements. There is no indication of a full annual or interim report, financial statements, or management discussion. The document is not a proxy solicitation or a meeting presentation but an official declaration of voting results. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and focused on voting results, consistent with DVA filings.
2017-11-15 Chinese
2017年第六次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as materials for the 2017 sixth extraordinary shareholders meeting (临时股东大会会议资料) of KPC Pharmaceuticals, Inc. It contains detailed meeting agenda, voting procedures, and a specific proposal regarding the change of a fundraising project. The content is focused on the meeting organization, agenda, and shareholder voting instructions rather than financial statements or earnings data. It is not a full annual or interim report, nor an earnings release or audit report. It is not a voting results announcement but the meeting materials themselves. Therefore, this document fits the category of AGM Information (AGM-R), which includes presentations and materials shared during a general meeting.
2017-11-06 Chinese
东海证券股份有限公司关于昆药集团股份有限公司变更部分募集资金投资项目的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from Donghai Securities, the sponsor institution, regarding the change of certain fundraising investment projects by Kunming Pharmaceutical Group Co., Ltd. It discusses the original fundraising project, the reasons for the change, the new project details, financial and technical indicators, and approvals from the board, supervisory committee, and independent directors. The document references compliance with Shanghai Stock Exchange fundraising management rules and includes detailed financial and project data. It is not a brief announcement but a substantive report on the change of use of raised funds, including financial figures and project specifics. This fits the category of Capital/Financing Update (CAP), as it concerns updates on company fundraising and capital use changes. The document length (5388 characters) supports it being a full report rather than a mere announcement. Therefore, the classification is CAP with high confidence.
2017-10-30 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.